2017-03-15,Summit Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference
2017-02-28,Summit Therapeutics Recognises 10th Annual Rare Disease Day
2017-02-02,Summit Therapeutics To Participate In February Investor Conferences
2017-02-01,Summit Outlines Phase 3 Programme For Novel CDI Antibiotic Ridinilazole Following FDA And EMA Regulatory Meetings
2017-01-18,Summit Appoints Dr David Roblin As Chief Operating Officer And President Of Research & Development
2016-12-15,Summit Therapeutics Reports Financial Results For The Third Quarter Ended 31 October 2016 And Operational Progress
2016-12-13,Summit Therapeutics To Report Financial Results For The Third Quarter Ended 31 October 2016 On 15 December 2016
2016-11-16,Summit Enrols Patients In The United States Into PhaseOut DMD, A Phase 2 Clinical Trial Of Ezutromid In Patients With DMD
2016-10-06,Summit Therapeutics Presents Preclinical DMD Data At The 21st International Congress Of The World Muscle Society
2016-10-04,Trending Tickers: SDRL, P, SMMT, SRPT
2016-10-04,Summit Therapeutics Soars on Sarepta Deal
2016-10-04,Summit Therapeutics (SMMT) Stock Spikes on Sarepta Licensing Deal
2016-10-04,Summit To Host Conference Call To Discuss Exclusive License And Collaboration Agreement With Sarepta Therapeutics For European Rights To Summit's Utrophin Modulator Pipeline For The Treatment Of Duchenne Muscular Dystrophy
2016-10-04,Sarepta Therapeutics And Summit Enter Into Exclusive License And Collaboration Agreement For European Rights To Summit's Utrophin Modulator Pipeline For The Treatment Of Duchenne Muscular Dystrophy
2016-09-27,Summit Receives Rare Pediatric Disease Designation From US FDA For Ezutromid In Treatment Of Duchenne Muscular Dystrophy
2016-09-26,Summit Receives Fast Track Designation From US FDA For Ezutromid In The Treatment Of Duchenne Muscular Dystrophy
2016-09-12,Summit Launches Online Resource On Utrophin Modulation For The Duchenne Muscular Dystrophy Community
2016-09-08,Summit Therapeutics Reports Financial Results For The Second Quarter Ended 31 July 2016 And Operational Progress
2016-09-07,Summit Therapeutics To Present At 18th Annual Rodman & Renshaw Global Investment Conference
2016-09-05,Summit Therapeutics To Report Financial Results For The Second Quarter Ended 31 July 2016 On 8 September 2016
2016-08-09,Summit Reports Positive Phase 1 New Formulation Data And Outlines Route To Market Strategy For DMD Candidate Ezutromid
2016-08-05,Summit Therapeutics To Present At Canaccord Genuity Growth Conference
2016-06-20,Summit's Ridinilazole Preserves Microbiome During Treatment Of C. Difficile Infection
2016-06-17,First Patient Enrolled In Summit's PhaseOut DMD, A Phase 2 Clinical Trial Of Ezutromid In Boys With DMD
2016-06-16,Summit Therapeutics To Present At JMP Securities Life Sciences Conference
2016-06-08,Summit Therapeutics To Host Utrophin R&D Day 15 June 2016
2016-06-02,Summit Therapeutics Reports Financial Results For The First Quarter Ended 30 April 2016 And Operational Progress
2016-05-31,Summit Therapeutics To Report Financial Results For The First Quarter Ended 30 April 2016 On 2 June 2016
2016-05-23,Summit To Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation Of The Microbiome In CDI Patients At ASM Microbe 2016
2016-05-11,Ratings Changes Today
2016-05-10,Summit Therapeutics Reports Financial Results For The Fourth Quarter And Fiscal Year Ended 31 January 2016
2016-05-06,Summit Therapeutics Provides Notice Of Financial Results For The Fourth Quarter And Fiscal Year Ended 31 January 2016
2016-04-28,Summit Announces Further US Patent Granted For CDI Antibiotic Ridinilazole
2016-04-26,Summit's IND Cleared By FDA Allowing Expansion Of PhaseOut DMD, A Phase 2 Clinical Trial Of Ezutromid (SMT C1100), Into The US
2016-04-11,Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential Of Ridinilazole In The Treatment Of C. Difficile Infection
2016-04-06,Summit Therapeutics To Present At 15th Annual Needham Healthcare Conference
2016-03-30,Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing A New Formulation Of SMT C1100 In Patients With DMD
2016-03-29,Summit To Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole's Statistical Superiority Over Vancomycin In Sustained Clinical Response Was Driven By Marked Reduction In Recurrence Of C. Difficile Infection
2016-03-15,Summit Announces Publication On Biomarkers To Quantify Utrophin Protein And Regeneration Of Muscle Fibres In DMD
2016-03-07,Summit Announces Ridinilazole Preserves The Gut Microbiome Of Patients With C. Difficile Infection In Phase 2 Trial
2016-02-29,Summit Therapeutics Supports Ninth Annual Rare Disease Day
2016-02-24,Summit Therapeutics Announces Publication Of Preclinical Data Showing Ridinilazole Outperformed Standard Of Care In Reducing C. Difficile Toxins That Drive Disease Symptoms
2016-02-17,Summit Therapeutics To Participate In SunTrust Robinson Humphrey's 2016 Orphan Drug Day
2016-02-03,Summit Therapeutics To Present At 18th Annual BIO CEO & Investor Conference
2016-01-21,Summit Therapeutics Receives Regulatory Approval To Initiate PhaseOut DMD, A Phase 2 Clinical Trial Of SMT C1100 In Patients With DMD
2016-01-19,Summit Therapeutics Granted Key European Patent For Novel Antibiotic Ridinilazole For Treatment Of C. Difficile Infection
2015-12-17,Summit Therapeutics Reports Financial Results For The Third Quarter Ended 31 October 2015 And Operational Progress
2015-12-14,Summit Therapeutics To Report Financial Results For The Third Quarter Ended 31 October 2015 On 17 December 2015
2015-12-10,Summit Therapeutics To Participate In The JMP Securities DMD Forum
2015-12-03,Summit Therapeutics To Present At The 26th Annual Oppenheimer Healthcare Conference
2015-12-02,Summit Therapeutics Announces First Milestone Achieved In Strategic Alliance With University Of Oxford For Future Generation Utrophin Modulators For Treatment Of DMD
2015-11-25,Summit Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-23,Summit Therapeutics Announces Novel Antibiotic Ridinilazole (SMT19969) Achieves Statistical Superiority Over Vancomycin In CoDIFy Phase 2 Clinical Trial For C. Difficile Infection
2015-11-17,Summit Therapeutics And The University Of Oxford Announce Multi-Year Extension Of Strategic Alliance For Development Of Utrophin Modulators For DMD
2015-11-02,Oversold Conditions For Summit Therapeutics (SMMT)
2015-09-30,Summit Therapeutics Presents Additional Data From Phase 1b Modified Diet Clinical Trial Of SMT C1100 In DMD Patients At WMS
2015-09-29,Summit Therapeutics Becomes Oversold (SMMT)
2015-09-24,Summit Therapeutics To Present Phase 1b Clinical And Preclinical DMD Data At The 20th International Congress Of The World Muscle Society
2015-09-18,Summit Therapeutics Presents New Positive Preclinical Data On Novel C. Difficile Antibiotic SMT19969 At ICAAC 2015
2015-09-10,Summit Therapeutics Completes Targeted Enrolment For SMT19969 Phase 2 Trial For C. Difficile Infection
2015-09-02,Summit Therapeutics Appoints Ralf Rosskamp, MD, As Chief Medical Officer
2015-08-27,Summit Therapeutics Reports Financial Results For The Second Quarter Ended 31 July 2015 And Operational Progress
2015-08-24,Summit Therapeutics To Report Second Quarter 2015 Financial Results On 27 August 2015
2015-08-17,Summit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective In Duchenne Muscular Dystrophy
2015-07-14,Summit Therapeutics Plc Annual General Meeting Statement
2015-07-13,Summit Therapeutics Publishes Preclinical Data On Disease-Modifying Potential Of Utrophin Modulation In DMD
2015-07-08,Summit Therapeutics Receives FDA Fast Track Designation For Novel Antibiotic SMT19969 In The Treatment Of C. Difficile Infection
2015-07-07,Summit Therapeutics Granted Key Patent By European Patent Office For Utrophin Modulator SMT C1100 In The Treatment Of DMD
2015-06-19,Summit Therapeutics To Present New Preclinical Data On Utrophin Modulator Programme At PPMD Connect Conference
2015-06-15,Summit To Present At JMP Securities Life Sciences Conference
2015-06-11,Summit Therapeutics Reports First Quarter Results For The Three Months Ended 30 April 2015
2015-06-05,Summit Therapeutics To Report First Quarter 2015 Financial Results On 11 June 2015
2015-05-06,Summit Therapeutics Reports Financial Results For The Fiscal Year Ended 31 January 2015
2015-05-01,Summit Therapeutics Provides Notice Of Full Year Financial Results
2015-04-30,Summit Therapeutics Granted Key Patent For Novel Antibiotic SMT19969 For The Treatment Of C. Difficile Infection
2015-04-17,IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up
2015-04-07,Summit To Present At Needham And Company's Annual Healthcare Conference
2015-03-18,Summit Therapeutics Announces Exercise Of Over-Allotment Option
2015-03-10,Summit Therapeutics Announces Closing Of Its U.S. Initial Public Offering
,
,
,
